查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1961042

全球侧向层析检测市场：市场规模、产业趋势、机会分析及预测（2026-2035年），依产品/服务、适应症、技术、最终用户、通路及地区划分

Global Lateral Flow Assay Market: By Product & Services, Indications, Technique, End User, Distribution Channel, Region - Market Size, Industry Dynamics, Opportunity Analysis and Forecast for 2026-2035
出版日期: | 出版商: Astute Analytica | 英文 219 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

全球侧向层析检测（LFA）市场正经历显着成长，预计到2025年将达到约 108.4亿美元。该成长趋势预计将持续稳定推进，到2035年将成长至约 176.6亿美元，2026年至2035年的年复合成长率约为 5.0%。市场扩张主要受几个关键因素驱动，其中最显着的是灵敏度不断提高，接近实验室等级，以及数位连接的整合。

先进技术与便携性的结合对于未来分散式医疗保健非常重要，使在传统实验室环境之外也能进行快速且准确的诊断。以紧凑、易用的形式提供实验室级的灵敏度，使医护人员和患者能够在各种环境下及时进行检测，从诊所到偏远地区，甚至在家中。这种能力不仅透过快速诊断和治疗改善患者预后，还透过实现广泛的筛检和监测，支持更广泛的公共卫生措施。

市场趋势

侧向层析侦测市场的竞争格局高度集中，主要由 QuidelOrtho、Abbott和Roche等产业巨头主导。这些领导企业凭藉其庞大的规模和深厚的监管专业知识，保持着市场主导地位。它们在从产品开发到监管合规等各个业务环节的高效运营，使其比规模较小的竞争对手拥有显着优势。例如，QuidelOrtho 公布的2024年至今经常性收入为 17.4亿美元，充分展现了其市场实力。

这些公司的优势源自于它们能够驾驭日益复杂和严格的诊断设备监管法规。例如，FDA 510（k）审批是产品上市的关键步骤，平均审批时间约 168.9 天，有效管理此流程需要丰富的专业知识、资源和策略规划。像 QuidelOrtho、Abbott和Roche这样的大公司拥有足够的资金来应对漫长的审批流程，同时保持营运动力。

此外，这些公司在研发方面投入巨资，能够不断创新并拓展产品组合。庞大的研发预算使它们能够推动新技术发展，提高检测精度，并快速应对新出现的健康挑战。这种雄厚的财力、监管敏锐度和创新能力的结合，不仅确保了它们的市场领导地位，也提高了小型公司的进入门槛。

核心成长驱动因子

新冠疫情后，医疗保健模式的重大重组塑造侧向层析检测市场的需求趋势，并明显转向分散式检测方法。全球医疗系统都在积极寻求缓解医院压力的方法，因为在传染病爆发期间，医院常常不堪负荷。这种策略转变凸显了快速即时诊断（POC）解决方案的重要性，这些解决方案可以在传统临床环境之外进行，加快决策速度并减少不必要的就医。

新机会趋势

改变侧向层析检测市场的最具创新性的趋势之一是，人们不断努力以便携、易用的形式实现 "实验室级的灵敏度" 。传统上，侧向层析检测因其速度和便利性而备受青睐，但在灵敏度和准确性方面却落后于实验室方法。这项进步代表着重大飞跃。2024年，随着基于CRISPR技术的侧向层析检测达到前所未有的0.25拷贝/μL的灵敏度阈值，这一差距开始显着缩小。这一检测水准对聚合酶炼式反应（PCR）技术构成了挑战，后者多年来一直主导着某些诊断应用，并有望在传统实验室环境之外实现快速、高灵敏度的检测。

最佳化障碍

儘管侧向层析检测（LFA）因其快速出结果和易用性而广受讚誉，但与更先进的实验室方法（例如聚合酶炼式反应（PCR）检测）相比，其灵敏度和特异性通常有限。这种固有的挑战可能导致假阳性或假阴性结果，这给医护人员和患者都带来了重大担忧。假阳性结果会导致不必要的焦虑、额外的检查和不恰当的治疗，而假阴性结果则可能导致漏诊和延误治疗，进而可能导致健康状况恶化和传染病传播。

目录

第1章 研究架构

  • 研究目标
  • 产品概述
  • 市场区隔

第2章 研究方法

  • 定性研究
    • 一手和二手资料来源
  • 量化研究
    • 一手和二手资料来源
  • 依地区划分的一手调查受访者组成
  • 研究假设
  • 市场规模估算
  • 资料三角验证

第3章 执行摘要：全球侧向流动免疫层析检测市场

第4章 全球侧向流动免疫层析检测市场概要

  • 产业价值链分析
    • 原料供应商
    • 製造商
    • 服务提供者
    • 最终用户
  • 行业展望
    • 即时诊断设备的各种应用
  • PESTLE 分析
  • 波特五力分析
    • 供应商议价能力
    • 买方议价能力
    • 替代品威胁
    • 新进入者威胁
    • 竞争强度
  • 市场动态与趋势
    • 成长驱动因素
    • 限制因素
    • 挑战
    • 主要趋势
  • 新冠疫情对市场的影响评估成长趋势
  • 市场成长与展望
    • 市场收入估计与预测（2020-2035）
    • 依产品划分的价格趋势分析
  • 竞争格局概览
    • 市场集中度
    • 公司市场占有率分析（2025）
    • 竞争格局图

第5章 侧向层析检测市场分析：依产品/服务划分

  • 主要发现
  • 市场规模及预测，2020-2035
    • 阅读器
    • LFA试剂盒

第6章 侧向层析检测市场分析：依适应症划分

  • 主要发现
  • 市场规模及预测，2020-2035
    • 传染病
    • 妊娠检测
    • 药物滥用检测

第7章 侧向层析检测市场依技术分类分析

  • 主要发现
  • 市场规模及预测（2020-2035）
    • 夹心法检测
    • 竞争法检测
    • 多重检测法检测

第8章 侧向层析侦测市场分析：依最终使用者

  • 主要发现
  • 市场规模及预测（2020-2035）
    • 医院和诊所
    • 诊断实验室
    • 家庭医疗保健环境
    • 製药和生技公司
    • 其他

第9章 侧向层析侦测市场分析：依通路

  • 主要发现
  • 市场规模及预测（2020-2035）
    • 医院药房
    • 零售药房
    • 超商/大型超市
    • 电子商务

第10章 侧向层析检测市场分析：依地区

  • 主要见解
  • 市场规模及预测（2020-2035）
    • 北美
    • 欧洲
    • 亚太地区
    • 中东和非洲
    • 南美

第11章 北美侧向层析侦测市场分析

第12章 欧洲侧向层析检测市场分析

第13章 亚太地区侧向层析侦测市场分析

第14章 中东与非洲侧向层析检测市场分析

第15章 南美洲侧向层析检测市场分析

第16章 公司简介

  • Abbott Laboratories
  • bioMerieux S.A
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • Merck KGaA
  • PerkinElmer Inc.
  • Qiagen N.V.
  • Quidel Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.,
  • Other Prominent Players
简介目录
Product Code: AA0522239

The global lateral flow assay (LFA) market is undergoing substantial growth, with its valuation reaching approximately USD 10.84 billion in 2025. This upward trajectory is expected to continue robustly, with projections estimating the market will expand to around USD 17.66 billion by 2035. This growth corresponds to a compound annual growth rate (CAGR) of about 5.0% over the forecast period from 2026 to 2035. The expansion of the market is driven by several key factors, most notably the increasing integration of digital connectivity with enhanced assay sensitivity that approaches laboratory-grade performance.

This fusion of advanced technology and portability is critical to the future of decentralized healthcare, where rapid, accurate diagnostics can be performed outside traditional laboratory settings. The ability to deliver lab-quality sensitivity in a compact, user-friendly format empowers healthcare providers and patients alike to conduct timely testing in diverse environments, from clinics to remote locations and even at home. Such capabilities not only improve patient outcomes through faster diagnosis and treatment but also support broader public health initiatives by enabling widespread screening and monitoring.

Noteworthy Market Developments

The competitive landscape of the lateral flow assay market is largely consolidated, dominated by major industry players such as QuidelOrtho, Abbott, and Roche. These giants leverage their substantial scale and deep regulatory expertise to maintain a commanding presence in the market. Their ability to operate efficiently across multiple facets of the business-from product development to regulatory compliance-gives them a significant advantage over smaller competitors. For instance, QuidelOrtho has demonstrated its market strength with reported recurring revenues of USD 1.74 billion year-to-date in 2024.

The dominance of these companies is underpinned by their capability to navigate the increasingly complex and stringent regulatory pathways that govern diagnostic devices. For example, the average review time for FDA 510(k) clearance-a critical step for market authorization-stands at approximately 168.9 days, a process that requires significant expertise, resources, and strategic planning to manage effectively. Large players like QuidelOrtho, Abbott, and Roche are equipped with the capital necessary to endure these lengthy approval processes without compromising their operational momentum.

Moreover, these companies invest heavily in research and development, enabling them to innovate and expand their product portfolios. Their substantial R&D budgets allow them to advance new technologies, improve test accuracy, and respond rapidly to emerging health challenges. This combination of financial strength, regulatory acumen, and innovation capacity not only secures their market leadership but also creates high barriers to entry for smaller firms.

Core Growth Drivers

The demand trajectory of the lateral flow assay market is being shaped by a fundamental restructuring of healthcare models in the aftermath of the COVID-19 pandemic, with a clear shift toward decentralized testing approaches. Healthcare systems worldwide are actively seeking to alleviate the strain on hospitals, which have frequently been overwhelmed by surges in patient volume during infectious disease outbreaks. This strategic pivot emphasizes the importance of rapid, point-of-care (POC) diagnostic solutions that can be administered outside traditional clinical settings, enabling quicker decision-making and reducing unnecessary hospital visits.

Emerging Opportunity Trends

One of the most transformative trends reshaping the lateral flow assay market is the ongoing effort to achieve "lab-quality" sensitivity within a portable, easy-to-use format. This advancement represents a significant leap forward, as traditionally, lateral flow assays have been valued for their speed and convenience but have lagged behind laboratory methods in terms of sensitivity and accuracy. In 2024, this gap began to narrow considerably with the validation of CRISPR-based lateral flow assays that achieved an unprecedented sensitivity threshold of 0.25 copy/μL. This level of detection challenges the long-standing dominance of polymerase chain reaction (PCR) techniques in certain diagnostic applications, offering the potential for rapid, highly sensitive testing outside of traditional laboratory settings.

Barriers to Optimization

Lateral flow assays (LFAs), while widely appreciated for their rapid results and ease of use, often face limitations in sensitivity and specificity when compared to more sophisticated laboratory-based methods such as polymerase chain reaction (PCR) testing. This inherent challenge can result in false-positive or false-negative outcomes, which pose significant concerns for both healthcare providers and patients. False positives may cause unnecessary anxiety, additional testing, and inappropriate treatments, while false negatives carry the risk of missed diagnoses and delayed care, potentially exacerbating health conditions and contributing to the spread of infectious diseases.

Detailed Market Segmentation

By Product, the lateral flow assay market is fundamentally shaped by a high-volume "razor-and-blade" business model, which has resulted in lateral flow assay (LFA) kits commanding a dominant 71.9% share of the market. This model hinges on the continuous and recurring consumption of disposable test strips, which are essential for conducting individual diagnostic tests. While readers and software systems provide the necessary infrastructure to interpret and analyze test results, the bulk of the industry's revenue is generated from the steady demand for these single-use kits. This recurring revenue stream is crucial for sustaining the financial health of diagnostic manufacturers and fueling ongoing innovation within the sector.

By Indication, diagnosing infectious diseases represents the largest segment of the lateral flow assay market, capturing an impressive 72.2% share. This dominance reflects the critical role that lateral flow technology plays in the detection and management of infectious diseases worldwide, particularly during global health crises. The widespread adoption of these assays is driven not only by the seasonal surges of respiratory viruses such as influenza and COVID-19 but also by ongoing, large-scale international testing initiatives targeting endemic and high-burden infectious diseases.

By Technique, the sandwich assay technique holds a commanding position in the lateral flow assay market, controlling nearly 48% of the total share. This dominance is largely due to the method's scientific superiority and its suitability for detecting high-molecular-weight analytes, which represent some of the most commonly targeted substances within the industry. High-molecular-weight analytes often include vital proteins and biomarkers that are essential for diagnosing a wide range of diseases and conditions. Because these targets are prevalent and clinically significant, the sandwich assay format has become the preferred choice for many lateral flow applications.

By End Users, hospitals and clinics hold a dominant position in the lateral flow assay market, accounting for 38.8% of the total market share. This leadership is largely attributed to the preference within professional healthcare settings for higher-value, multiplexed diagnostic tests. These advanced assays can detect multiple analytes simultaneously, providing comprehensive diagnostic information that is crucial for managing complex medical conditions. Because of their sophistication and enhanced capabilities, these multiplexed diagnostics command significantly higher average selling prices (ASPs) compared to simpler home testing kits, making the hospital and clinic segment a highly valuable part of the market.

Segment Breakdown

By Product & Services:

  • Readers
  • Bench-top Readers
  • Hand-held Readers
  • LFA Kits
  • Test Strips
  • Dipsticks
  • Cassettes
  • Lancets

By Indications:

  • Infectious Diseases
  • Mosquito-borne Diseases
  • Streptococcus Infections
  • Sexually Transmitted Diseases
  • Hepatitis
  • Tuberculosis
  • Asthma
  • Pneumonia
  • Sepsis
  • Gastrointestinal Infections
  • Others
  • Pregnancy Test
  • Drug of Abuse Testing

By Technique:

  • Sandwich Assays
  • Competitive Assays
  • Multiplex Detection Assays

By End User:

  • Hospitals & Clinics
  • Diagnostics Laboratories
  • Home Care Settings
  • Pharmaceuticals & Biotechnology Companies
  • Other

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Supermarkets/ Hypermarkets
  • e-Commerce

By Region:

  • North America
  • The U.S.
  • Canada
  • Mexico
  • Europe
  • Western Europe
  • The UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Western Europe
  • Eastern Europe
  • Poland
  • Russia
  • Rest of Eastern Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN
  • Rest of Asia Pacific
  • Middle East & Africa (MEA)
  • UAE
  • Saudi Arabia
  • South Africa
  • Rest of MEA
  • South America
  • Argentina
  • Brazil
  • Rest of South America

Geography Breakdown

  • North America holds a commanding position in the lateral flow assay market, capturing a significant 34.90% share that is largely driven by the United States. This dominance is underpinned by the country's highly efficient regulatory framework and the pressing clinical demands placed on its healthcare system. The United States has established itself as a global leader in facilitating the rapid approval and deployment of diagnostic technologies, creating an environment that encourages innovation and swift market entry.
  • This regulatory agility is not merely a bureaucratic achievement but a direct response to urgent healthcare needs within the country. The U.S. faces a substantial clinical burden, exemplified by an estimated 40 million influenza cases annually and approximately 470,000 hospitalizations recorded in the most recent flu season. Such high incidence rates place enormous strain on healthcare resources, necessitating efficient and reliable diagnostic tools to manage patient flow and treatment decisions effectively.

Leading Market Participants

  • Abbott Laboratories
  • bioMerieux S.A
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Hologic Inc.
  • Merck KGaA
  • PerkinElmer Inc.
  • Qiagen N.V.
  • Quidel Corporation
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.,
  • Other Prominent Players

Table of Content

Chapter 1. Research Framework

  • 1.1. Research Objective
  • 1.2. Product Overview
  • 1.3. Market Segmentation

Chapter 2. Research Methodology

  • 2.1. Qualitative Research
    • 2.1.1. Primary & Secondary Sources
  • 2.2. Quantitative Research
    • 2.2.1. Primary & Secondary Sources
  • 2.3. Breakdown of Primary Research Respondents, By Region
  • 2.4. Assumption for the Study
  • 2.5. Market Size Estimation
  • 2.6. Data Triangulation

Chapter 3. Executive Summary: Global Lateral Flow Assay Market

Chapter 4. Global Lateral Flow Assay Market Overview

  • 4.1. Industry Value Chain Analysis
    • 4.1.1. Material Provider
    • 4.1.2. Manufacturer
    • 4.1.3. Service Provider
    • 4.1.4. End-User
  • 4.2. Industry Outlook
    • 4.2.1. Various Applications of Point of Care Diagnostic Devices
  • 4.3. PESTLE Analysis
  • 4.4. Porter's Five Forces Analysis
    • 4.4.1. Bargaining Power of Suppliers
    • 4.4.2. Bargaining Power of Buyers
    • 4.4.3. Threat of Substitutes
    • 4.4.4. Threat of New Entrants
    • 4.4.5. Degree of Competition
  • 4.5. Market Dynamics and Trends
    • 4.5.1. Growth Drivers
    • 4.5.2. Restraints
    • 4.5.3. Challenges
    • 4.5.4. Key Trends
  • 4.6. Covid-19 Impact Assessment on Market Growth Trend
  • 4.7. Market Growth and Outlook
    • 4.7.1. Market Revenue Estimates and Forecast (US$ Bn), 2020 - 2035
    • 4.7.2. Price Trend Analysis, by product
  • 4.8. Competition Dashboard
    • 4.8.1. Market Concentration Rate
    • 4.8.2. Company Market Share Analysis (Value %), 2025
    • 4.8.3. Competitor Mapping

Chapter 5. Lateral Flow Assay Market Analysis, By Product & Services

  • 5.1. Key Insights
  • 5.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 5.2.1. Readers
      • 5.2.1.1. Bench-top Readers
      • 5.2.1.2. Hand-held Readers
    • 5.2.2. LFA Kits
      • 5.2.2.1. Test Strips
      • 5.2.2.2. Dipsticks
      • 5.2.2.3. Cassettes
      • 5.2.2.4. Lancets

Chapter 6. Lateral Flow Assay Market Analysis, By Indications

  • 6.1. Key Insights
  • 6.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 6.2.1. Infectious Diseases
      • 6.2.1.1. Mosquito-borne Diseases
      • 6.2.1.2. Streptococcus Infections
      • 6.2.1.3. Sexually Transmitted Diseases
      • 6.2.1.4. Hepatitis
      • 6.2.1.5. Tuberculosis
      • 6.2.1.6. Asthma
      • 6.2.1.7. Pneumonia
      • 6.2.1.8. Sepsis
      • 6.2.1.9. Gastrointestinal Infections
      • 6.2.1.10. Others
    • 6.2.2. Pregnancy Test
    • 6.2.3. Drug of Abuse Testing

Chapter 7. Lateral Flow Assay Market Analysis, By Technique

  • 7.1. Key Insights
  • 7.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 7.2.1. Sandwich Assays
    • 7.2.2. Competitive Assays
    • 7.2.3. Multiplex Detection Assays

Chapter 8. Lateral Flow Assay Market Analysis, By End User

  • 8.1. Key Insights
  • 8.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 8.2.1. Hospitals & Clinics
    • 8.2.2. Diagnostics Laboratories
    • 8.2.3. Home Care Settings
    • 8.2.4. Pharmaceuticals & Biotechnology Companies
    • 8.2.5. Other

Chapter 9. Lateral Flow Assay Market Analysis, By Distribution Channel

  • 9.1. Key Insights
  • 9.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 9.2.1. Hospital Pharmacies
    • 9.2.2. Retail Pharmacies
    • 9.2.3. Supermarkets/Hypermarkets
    • 9.2.4. e-Commerce

Chapter 10. Lateral Flow Assay Market Analysis, By Region

  • 10.1. Key Insights
  • 10.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 10.2.1. North America
      • 10.2.1.1. The U.S.
      • 10.2.1.2. Canada
      • 10.2.1.3. Mexico
    • 10.2.2. Europe
      • 10.2.2.1. Western Europe
        • 10.2.2.1.1. The UK
        • 10.2.2.1.2. Germany
        • 10.2.2.1.3. France
        • 10.2.2.1.4. Italy
        • 10.2.2.1.5. Spain
        • 10.2.2.1.6. Rest of Western Europe
      • 10.2.2.2. Eastern Europe
        • 10.2.2.2.1. Poland
        • 10.2.2.2.2. Russia
        • 10.2.2.2.3. Rest of Eastern Europe
    • 10.2.3. Asia Pacific
      • 10.2.3.1. China
      • 10.2.3.2. India
      • 10.2.3.3. Japan
      • 10.2.3.4. South Korea
      • 10.2.3.5. Australia & New Zealand
      • 10.2.3.6. ASEAN
      • 10.2.3.7. Rest of Asia Pacific
    • 10.2.4. Middle East & Africa
      • 10.2.4.1. UAE
      • 10.2.4.2. Saudi Arabia
      • 10.2.4.3. South Africa
      • 10.2.4.4. Rest of MEA
    • 10.2.5. South America
      • 10.2.5.1. Argentina
      • 10.2.5.2. Brazil
      • 10.2.5.3. Rest of South America

Chapter 11. North America Lateral Flow Assay Market Analysis

  • 11.1. Key Insights
  • 11.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 11.2.1. By Product & Services
    • 11.2.2. By Indication
    • 11.2.3. By Technique
    • 11.2.4. By End User
    • 11.2.5. By Distribution Channel
    • 11.2.6. By Country

Chapter 12. Europe Lateral Flow Assay Market Analysis

  • 12.1. Key Insights
  • 12.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 12.2.1. By Product & Services
    • 12.2.2. By Indication
    • 12.2.3. By Technique
    • 12.2.4. By End User
    • 12.2.5. By Distribution Channel
    • 12.2.6. By Country

Chapter 13. Asia Pacific Lateral Flow Assay Market Analysis

  • 13.1. Key Insights
  • 13.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 13.2.1. By Product & Services
    • 13.2.2. By Indication
    • 13.2.3. By Technique
    • 13.2.4. By End User
    • 13.2.5. By Distribution Channel
    • 13.2.6. By Country

Chapter 14. Middle East and Africa Lateral Flow Assay Market Analysis

  • 14.1. Key Insights
  • 14.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 14.2.1. By Product & Services
    • 14.2.2. By Indication
    • 14.2.3. By Technique
    • 14.2.4. By End User
    • 14.2.5. By Distribution Channel
    • 14.2.6. By Country

Chapter 15. South America Lateral Flow Assay Market Analysis

  • 15.1. Key Insights
  • 15.2. Market Size and Forecast, 2020 - 2035 (US$ Bn)
    • 15.2.1. By Product & Services
    • 15.2.2. By Indication
    • 15.2.3. By Technique
    • 15.2.4. By End User
    • 15.2.5. By Distribution Channel
    • 15.2.6. By Country

Chapter 16. Company Profile (Company Overview, Financial Matrix, Key Product landscape, Key Personnel, Key Competitors, Contact Address, and Business Strategy Outlook)

  • 16.1. Abbott Laboratories
  • 16.2. bioMerieux S.A
  • 16.3. Bio-Rad Laboratories Inc.
  • 16.4. Danaher Corporation
  • 16.5. F. Hoffmann-La Roche Ltd.
  • 16.6. Hologic Inc.
  • 16.7. Merck KGaA
  • 16.8. PerkinElmer Inc.
  • 16.9. Qiagen N.V.
  • 16.10. Quidel Corporation
  • 16.11. Siemens Healthineers
  • 16.12. Thermo Fisher Scientific, Inc.,
  • 16.13. Other Prominent Players